Back to News
Market Impact: 0.15
Kairos Pharma Presents at United Scientific Group's 11th International Conference on Cancer Research & Drug Development
Source: businesswire.com
Healthcare & BiotechCompany Fundamentals
Kairos Pharma President and CSO Neil Bhowmick presented lead candidate ENV-105 and interim efficacy results at Cancer R&D 2026. The article provides no efficacy figures or further details, so the clinical significance cannot be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
KAPA0.30
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge